By: Victoria Perniola, Attorney
For healthcare providers, med spas, aesthetic practices, regenerative medicine clinics, and wellness businesses, the compliance question is rarely limited to: “Am I legally permitted to purchase this product?” The better operational question is: “Can I lawfully use, administer, market, and scale this product within my practice’s specific clinical delivery model?”
That distinction matters because vendor materials usually speak to the product in the vendor’s preferred context. They may describe a growth factor, regenerative, exosome-like, secretome, PDGF, post-procedure, peptide, or cell-derived product as a cosmetic or wellness offering. But those materials are not tailored to the provider’s license, the scope of practice rules of that particular state, corporate structure concerns, supervision requirements, consent documents, staff protocols, or patient-facing claims.
A vendor may be focused on the vial. The provider is responsible for the protocol.
Federal product and advertising rules, state professional standards, and clinic practice requirements can all apply to the same service line. That is why the provider’s actual use matters. The same vendor-supplied product can raise very different issues depending on how it is sourced, how it touches the patient, whether the skin barrier is disrupted, whether it is topical or injectable, who administers it, and what the practice says the treatment will do.
Where Vendor Claims Diverge from Clinical Reality
Regulatory risk for biological, peptide, and regenerative therapies and products is entirely dynamic and fact-specific. Three practice-level variables usually drive the analysis:
- The Route of Administration: A product marketed as a topical cosmetic intended to support the appearance of intact skin is not the same risk as a product applied after microneedling, radiofrequency (RF) microneedling, laser resurfacing, chemical peels, or another procedure that disrupts the skin barrier. It is also different from an injectable product. If the practice’s protocol introduces the product into broken skin or bypasses the ordinary skin barrier, generic vendor statements about “cosmetic” use may not answer the relevant legal question.
- The Scope of Patient Facing Claims: Vendors may use scientific or educational language to describe how to routinely incorporate structural and physiological terminology in their educational literature to explain how a product is intended to work. That language may reference “tissue healing,” “cellular regeneration,” “inflammation reduction,” “scar repair,” “hair regrowth”, “collagen stimulation”, or “biological anti-aging.” But when a practice repeats those phrases on their website, landing pages, advertisements, social media posts, patient FAQs, consent forms, before and after captions, or consultation scripts, the practice may create a separate FDA or FTC issue.
The difference between saying a treatment supports the appearance of smoother skin and saying it regenerates tissue, repairs scars, reduces inflammation, or treats hair loss, is not just branding. Those claims can affect whether the product or related marketing is viewed as promoting an unapproved drug or biologic use, or as making health-related claims that require appropriate substantiation.
- The Turnkey Risk Profile: “Everyone else is using it” is not a compliance strategy. In high-growth areas like aesthetics and regenerative medicine, market adoption can move faster than regulatory review. The fact that another clinic uses the same product, brochure, or social media language does not mean the product fits squarely withinyour protocol, your staff model, your state’s scope of practice rules, or your risk tolerance.
A Practical Vetting Framework for Vendors
Strong practices do not treat compliance as a launch blocker. They use a focused review process so promising service lines can be evaluated, structured, and marketed more cleanly from the beginning.
- Isolate the True Route of Administration: Define exactly how the product touches the patient. Is it used on intact skin, applied after a procedure that disrupts the skin barrier, mixed with another product, administered with a device, or injected? The answer materially changes the analysis.
- Audit the Practice Ecosystem, Not Just the Label: Review your digital assets such as website pages, social media before-and-after pictures and captions, landing pages, patient FAQs, internal staff consultation scripts, and vendor-provided materials. The goal is to align the practice’s messaging with supportable cosmetic or clinical claims and avoid language that suggests disease treatment, tissue regeneration, structural change, systemic healing, or guaranteed outcomes unless backed by an explicit regulatory pathway and there is a legally supportable basis for making those claims.
- Separate Product Validation from Practice Clearance: Treat vendor literature as helpful technical information, not a legal opinion. A provider still needs to evaluate product sourcing, intended use, route of administration, supervision requirements, your state’ scope of practice rules, corporate practice of medicine limitations, consent documents, and the substantiation supporting patient-facing materials and claims.
Compliance as a Growth Strategy
Proactive regulatory review is not a defensive chore that slows your practice down. If done correctly, it is a growth tool to build a high-value, scalable, and highly investable medical enterprise. A service line built with appropriate sourcing, well-documented protocols, supportable claims, clear consent language, and trained staff is easier to launch, market, scale, review, withstand diligence, and defend.
At Florida Healthcare Law Firm, we help healthcare providers, med spas, wellness businesses, and regenerative medicine practices evaluate product sourcing, service line expansion, advertising claims, consent forms, vendor materials, and FDA/FTC compliance risk before the service goes live.
Before relying on a vendor’s statement that a product is “compliant,” providers should confirm whether the product, proposed use, protocol, and marketing strategy actually fit the practice’s regulatory risk tolerance.
